ArticleTransplantation2026
Role of Histamine in Liver Ischemia-Reperfusion Injury-Implication for H1 Receptor Antagonist in the Clinical Application.
Article in Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Connecting Amino Acid Metabolism to Inflammatory Modulation in Liver Ischemia-Reperfusion Injury.Transplantation · 2026Article
- Desloratadine attenuates renal ischemia-reperfusion injury through activation of the Nrf2-GCL-GSH antioxidant pathway.Current research in pharmacology and drug discovery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver ischemia-reperfusion injury (IRI) is a critical complication of liver resection and transplantation. Our previous research demonstrated that preoperative fasting regimen significantly mitigated liver IRI in mice, whereas how fasting alleviates liver IRI remains largely unknown. In this study, we aimed to identify the metabolites that contribute to the pathology of liver IRI and to investigate their roles in modulating liver damage.
methodsComprehensive metabolomic analysis was performed on liver tissues obtained from wild-type (WT) mice subjected to partial warm liver ischemia and reperfusion with and without preoperative fasting. To investigate the role of histamine in liver IRI, histamine H1 receptor knockout (Hrh1KO) and WT mice were exposed to liver IRI. Some WT and Hrh1KO mice were pretreated with H1-antihistamines before the ischemia challenge.
resultsAmong the identified metabolites, histamine displayed a distinctive pattern, with significantly elevated levels in the ischemia and reperfusion insult group without preoperative fasting and substantially reduced levels in the preoperative fasting group. Significant amelioration of liver IRI was observed in Hrh1KO mice, accompanied by a profound reduction in the release of high-mobility group box 1 into the bloodstream. Furthermore, administration of H1-antihistamines, which block histamine binding to the histamine H1 receptor (H1R) and suppress basal H1R activity, significantly inhibited high-mobility group box 1 release and ameliorated liver IRI.
conclusionsHistamine is a key metabolite that exacerbates liver IRI via H1R-mediated signaling pathways. These findings highlight the potential of H1-antihistamines as a promising therapeutic approach for mitigating liver injury associated with liver surgery and liver transplantation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.